Impact of Dissolvable Tobacco Use on Public Health; Request for Comments, 13556-13557 [2010-6216]
Download as PDF
13556
Federal Register / Vol. 75, No. 54 / Monday, March 22, 2010 / Notices
Fishery Products — Decomposition,
which is available on the Internet at
https://www.fda.gov/ICECI/Compliance
Manuals/CompliancePolicyGuidance
Manual/ucm123201.htm.
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
Dated: March 9, 2010.
Michael A. Chappell,
Acting Associate Commissioner for
Regulatory Affairs.
[FR Doc. 2010–6209 Filed 3–19–10; 8:45 am]
Dated: March 5, 2010.
Mitchell A. Cheeseman,
Acting Director, Office of Food Additive
Safety, Center for Food Safety and Applied
Nutrition.
BILLING CODE 4160–01–S
[FR Doc. 2010–6177 Filed 3–19–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Food and Drug Administration
[Docket No. FDA–2010–C–0077]
[Docket No. FDA–2010–N–0123]
Biocompatibles UK Ltd.; Filing of Color
Additive Petition
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
ACTION:
The Food and Drug
Administration (FDA) is announcing
that Biocompatibles UK Ltd., has filed a
petition proposing that the color
additive regulations be amended to
provide for the safe use of C.I. Reactive
Blue No. 4 [2-anthracenesulfonic acid,
1-amino-4-(3-((4,6-dichloro-s-triazin-2yl)amino)-4-sulfoanilino)-9,10-dihydro9,10-dioxo, disodium salt] (CAS Reg.
No. 4499–01–8) reacted with polyvinyl
alcohol as a color additive in vascular
embolization devices.
FOR FURTHER INFORMATION CONTACT:
Judith Kidwell, Center for Food Safety
and Applied Nutrition (HFS–265), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740–
3835, 301–436–1071.
SUPPLEMENTARY INFORMATION: Under the
Federal Food, Drug, and Cosmetic Act
(sec. 721(d)(1) (21 U.S.C. 379e(d)(1))),
notice is given that a color additive
petition (CAP 0C0288) has been filed by
Biocompatibles UK Ltd., c/o John
Greenbaum, Generic Devices
Consulting, Inc., 20310 SW. 48th St,
Southwest Ranches, FL 33332. The
petition proposes to amend the color
additive regulations in 21 CFR part 73,
subpart D, Medical Devices, to provide
for the safe use of C.I. Reactive Blue No.
4 [2-anthracenesulfonic acid, 1-amino-4(3-((4,6-dichloro-s-triazin-2-yl)amino)-4sulfoanilino)-9,10-dihydro-9,10-dioxo,
disodium salt] (CAS Reg. No. 4499–01–
8) reacted with polyvinyl alcohol as a
color additive in vascular embolization
devices.
The agency has determined under 21
CFR 25.32(l) that this action is of a type
that does not individually or
pwalker on DSK8KYBLC1PROD with NOTICES
SUMMARY:
16:41 Mar 19, 2010
AGENCY:
Food and Drug Administration,
HHS.
Notice.
VerDate Nov<24>2008
Impact of Dissolvable Tobacco Use on
Public Health; Request for Comments
Jkt 220001
Notice; request for comments.
SUMMARY: The Food and Drug
Administration (FDA) is establishing a
public docket to provide an opportunity
for interested parties to share
information, research, and ideas on how
use of dissolvable tobacco products may
impact public health, including such
use among children. This information
will be used to support the work of the
Tobacco Products Scientific Advisory
Committee, which is charged with
evaluating this issue.
DATES: Submit written or electronic
comments by [insert date 180 days from
date of publication in the Federal
Register].
Submit electronic
comments to https://
www.regulations.gov/. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Kathleen K. Quinn, Center for Tobacco
Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850–3229, 240–276–
1717, Kathleen.Quinn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
I. Background
Tobacco products are responsible for
more than 440,000 deaths each year.
The Centers for Disease Control and
Prevention report that every day in the
United States, approximately 3,900
young people between these ages of 12
and 17 smoke their first cigarette and
approximately 1,000 adolescents
become daily smokers. Multiple studies
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
have shown that adolescents who use
smokeless tobacco products are more
likely to become smokers than those
who do not.
Dissolvable tobacco products are a
novel class of smokeless tobacco
products, which are sold as thin strips,
tablets, and sticks resembling
toothpicks. Because some of these
products look like candy, are highly
flavored, and can be easily concealed,
public health officials have raised
concerns that dissolvable tobacco
products may be particularly appealing
to children and adolescents. These
products also contain up to 4.0
milligrams of nicotine per unit, which
could facilitate initiation of tobacco use
and the development of nicotine
dependence in adolescents, or even
serve as a mechanism for inadvertent
toxicity in children.
On June 22, 2009, the President
signed the Family Smoking Prevention
and Tobacco Control Act (the Tobacco
Control Act) into law. The Tobacco
Control Act granted FDA important new
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect the public health
generally and to reduce tobacco use by
minors. Among its many provisions, the
Tobacco Control Act added section
907(f) to the Federal Food, Drug, and
Cosmetic Act (the act). This section
requires FDA to refer the issue of ‘‘the
nature and impact of the use of
dissolvable tobacco products on the
public health, including such use
among children’’ to a Tobacco Products
Scientific Advisory Committee, which
will be charged with providing FDA a
report and recommendations.
We are requesting comments that will
support the work of the Tobacco
Products Scientific Advisory Committee
in evaluating the public health impact
of dissolvable tobacco products. A copy
of the Tobacco Control Act is available
at https://www.fda.gov/tobacco.
II. Request for Comments and
Information
Data around the nature, impact, and
use of dissolvables tobacco products
will be critical to the Tobacco Products
Scientific Advisory Committee in
studying and reporting on their public
health impact. We are therefore
requesting comment, research, and data
on ways in which these products might
be used by individuals, including
children and adolescents, how the risks
of using these products are perceived by
smokers and non-smokers, and how use
of these products affects health. Such
research may address:
E:\FR\FM\22MRN1.SGM
22MRN1
Federal Register / Vol. 75, No. 54 / Monday, March 22, 2010 / Notices
• Perceptions of dissolvable tobacco
products from current tobacco users and
¨
tobacco-naıve individuals, by age;
• Marketing of dissolvable tobacco
products to current tobacco users and
¨
tobacco-naıve individuals, by age;
• Impact of dissolvable tobacco
products on initiation of tobacco use in
¨
tobacco-naıve individuals, by age;
• Dual use of dissolvable tobacco
products by current tobacco users;
• Impact of dissolvable tobacco
products on cessation of tobacco use;
• Risk of accidental ingestion of
dissolvable tobacco products;
• Risk of accidental nicotine toxicity
through use of dissolvable tobacco
products; and
• Consumer understanding of the
potential toxicity of dissolvable tobacco
products to children.
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified by the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: March 17, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Molecular and Cellular
Neuroscience.
Date: April 1, 2010.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: Laurent Taupenot, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4811,
MSC 7850, Bethesda, MD 20892. 301–435–
1203. taupenol@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Virology and Viral Immunity.
Date: April 6–7, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Richard G. Kostriken, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7808, Bethesda, MD 20892. 301–402–
4454. kostrikr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 15, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–6216 Filed 3–19–10; 8:45 am]
BILLING CODE 4160–01–S
[FR Doc. 2010–6107 Filed 3–19–10; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
pwalker on DSK8KYBLC1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Nov<24>2008
16:41 Mar 19, 2010
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
13557
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Eureka Meeting.
Date: April 15–16, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN12B, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Lisa A. Dunbar, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda, MD
20892, 301–594–2849, dunbarl@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: March 12, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–6112 Filed 3–19–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, LRP Reviews.
Date: May 7, 2010.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\22MRN1.SGM
22MRN1
Agencies
[Federal Register Volume 75, Number 54 (Monday, March 22, 2010)]
[Notices]
[Pages 13556-13557]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6216]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0123]
Impact of Dissolvable Tobacco Use on Public Health; Request for
Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is establishing a
public docket to provide an opportunity for interested parties to share
information, research, and ideas on how use of dissolvable tobacco
products may impact public health, including such use among children.
This information will be used to support the work of the Tobacco
Products Scientific Advisory Committee, which is charged with
evaluating this issue.
DATES: Submit written or electronic comments by [insert date 180 days
from date of publication in the Federal Register].
ADDRESSES: Submit electronic comments to https://www.regulations.gov/.
Submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Kathleen K. Quinn, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850-3229, 240-276-1717, Kathleen.Quinn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Tobacco products are responsible for more than 440,000 deaths each
year. The Centers for Disease Control and Prevention report that every
day in the United States, approximately 3,900 young people between
these ages of 12 and 17 smoke their first cigarette and approximately
1,000 adolescents become daily smokers. Multiple studies have shown
that adolescents who use smokeless tobacco products are more likely to
become smokers than those who do not.
Dissolvable tobacco products are a novel class of smokeless tobacco
products, which are sold as thin strips, tablets, and sticks resembling
toothpicks. Because some of these products look like candy, are highly
flavored, and can be easily concealed, public health officials have
raised concerns that dissolvable tobacco products may be particularly
appealing to children and adolescents. These products also contain up
to 4.0 milligrams of nicotine per unit, which could facilitate
initiation of tobacco use and the development of nicotine dependence in
adolescents, or even serve as a mechanism for inadvertent toxicity in
children.
On June 22, 2009, the President signed the Family Smoking
Prevention and Tobacco Control Act (the Tobacco Control Act) into law.
The Tobacco Control Act granted FDA important new authority to regulate
the manufacture, marketing, and distribution of tobacco products to
protect the public health generally and to reduce tobacco use by
minors. Among its many provisions, the Tobacco Control Act added
section 907(f) to the Federal Food, Drug, and Cosmetic Act (the act).
This section requires FDA to refer the issue of ``the nature and impact
of the use of dissolvable tobacco products on the public health,
including such use among children'' to a Tobacco Products Scientific
Advisory Committee, which will be charged with providing FDA a report
and recommendations.
We are requesting comments that will support the work of the
Tobacco Products Scientific Advisory Committee in evaluating the public
health impact of dissolvable tobacco products. A copy of the Tobacco
Control Act is available at https://www.fda.gov/tobacco.
II. Request for Comments and Information
Data around the nature, impact, and use of dissolvables tobacco
products will be critical to the Tobacco Products Scientific Advisory
Committee in studying and reporting on their public health impact. We
are therefore requesting comment, research, and data on ways in which
these products might be used by individuals, including children and
adolescents, how the risks of using these products are perceived by
smokers and non-smokers, and how use of these products affects health.
Such research may address:
[[Page 13557]]
Perceptions of dissolvable tobacco products from current
tobacco users and tobacco-na[iuml]ve individuals, by age;
Marketing of dissolvable tobacco products to current
tobacco users and tobacco-na[iuml]ve individuals, by age;
Impact of dissolvable tobacco products on initiation of
tobacco use in tobacco-na[iuml]ve individuals, by age;
Dual use of dissolvable tobacco products by current
tobacco users;
Impact of dissolvable tobacco products on cessation of
tobacco use;
Risk of accidental ingestion of dissolvable tobacco
products;
Risk of accidental nicotine toxicity through use of
dissolvable tobacco products; and
Consumer understanding of the potential toxicity of
dissolvable tobacco products to children.
III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified by the docket number found in brackets in
the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Dated: March 17, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-6216 Filed 3-19-10; 8:45 am]
BILLING CODE 4160-01-S